ESTA Announces Participation in the Wells Fargo Virtual Healthcare Conference

Rhea-AI Summary

Establishment Labs Holdings Inc. (NASDAQ: ESTA) will participate in the 2020 Wells Fargo Virtual Healthcare Conference on September 9, 2020, at 2:00 PM ET. CEO Juan José Chacón-Quirós and CFO Renee Gaeta will represent the company. The event will be available via live webcast on the Establishment Labs investor relations website, with an archived version accessible post-event. Establishment Labs specializes in women's health, focusing on breast aesthetics and reconstruction, and offers products like Motiva Implants®, available in over 80 countries.

Positive

• Participation in a significant healthcare conference may enhance visibility and investor interest.
• The company's products, including Motiva Implants®, are available in over 80 countries, indicating strong market penetration.

Negative

• None.

NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Founder Juan José Chacón-Quirós and Chief Financial Officer Renee Gaeta will participate in the 2020 Wells Fargo Virtual Healthcare Conference, which is being held September 9-10, 2020. Mr. Chacón-Quirós and Ms. Gaeta are scheduled to speak to conference attendees at 2:00 pm ET on Wednesday, September 9, 2020.

A live webcast of the presentation will be available to all interested parties on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/.  An archived version of the webcast will be available on the same website following the completion of the event.

About Establishment Labs

Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a global medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company’s direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, Establishment Labs’ product and technologies portfolio includes the Divina® 3D Simulation System and other products and services. Please visit our website for additional information at www.establishmentlabs.com. 

Investor/Media Contact:
David K. Erickson 
Establishment Labs Holdings Inc. 
949-447-6671

FAQ

When will Establishment Labs participate in the Wells Fargo Virtual Healthcare Conference?

Establishment Labs will participate in the conference on September 9, 2020, at 2:00 PM ET.

Who from Establishment Labs will speak at the Wells Fargo conference?

CEO Juan José Chacón-Quirós and CFO Renee Gaeta will represent Establishment Labs.

What products does Establishment Labs focus on?

Establishment Labs focuses on women's health, specifically in breast aesthetics and reconstruction with products like Motiva Implants®.

In how many countries are Motiva Implants® available?

Motiva Implants® are available in over 80 countries.

Where can I find the webcast of the conference presentation?

The webcast will be available on the Establishment Labs investor relations website.